Interestingly, the mesenchymal-epithelial transition (MET) has been identified as a novel mechanism regulating PD-L1 stability in CSCs, with studies showing that targeting this pathway can enhance the efficacy of cancer immunotherapy (Sharaf et al., 2014). Here, CD274 is linked to cancer.